Abstract
Introduction

Immunoglobulin light chain-associated (AL) amyloidosis is a disease that presents several clinical symptoms due to amyloid deposition in systemic organs such as the heart, liver, kidney, tongue, gastrointestinal tract, skin, and peripheral nerves (1). Amyloid is a peculiar form of an insoluble fibrillar protein with a beta-pleated-sheet configuration, and amyloid fibrils trigger irreversible impairment of organ function. Cardiac amyloidosis has a poor prognosis, and the mean prognosis has been reported to be 6 months or after the onset of symptoms of heart failure (2-4). The amyloidogenic protein is an immunoglobulin light chain or a fragment of a light chain that is produced by a clonal population of plasma cells in bone marrow. Several treatments for AL amyloidosis based on treatment for multiple myeloma have been performed. These treatments include MP (melphalan and prednisolone) therapy (5-7), VAD (vincristine, doxorubicin, and dexamethasone) therapy
, interferon therapy (9) , and high-dose dexamethasone therapy (10) . However (Fig. 2A, B 
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4B). Although the patient had no history of heart failure and no symptoms or signs suggestive of congestive heart failure during or after chemotherapy, only a low-dose of candesartan (4 mg) was prescribed with the expectation of cardiac protection. Although the brain natriuretic peptide (BNP) level was 128 pg/mL before the transplantation, it was decreased to 56 pg/mL at 8 months after the transplantation and has been maintained at about 50 pg/mL for 3.5 years. The patient is still making outpatient visits with no decrease in quality of life and no elevation of BNP level for about 3.5 years since the diagnosis.
Discussion
The diagnosis of amyloidosis is based on histological findings in specimens from symptomatic organs. However, (12) . (8) , interferon therapy (9) , and high-dose dexamethasone therapy (10) have also been performed and improvement in clinical symptoms has been reported for some patients, but overall survival has not been extended significantly (13) (14) (15) .
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Treatment of AL amyloidosis has been directed towards reducing the production of amyloid precursors from plasma cells. However, removal of amyloid deposits is difficult and the prognosis of amyloidosis remains poor. MP therapy has been performed for the purpose of inhibiting the production of M proteins, but there have been no obvious clinical effects such as improvement in prognosis (5-7). Potent chemotherapies such as VAD therapy
In recent years, high-dose melphalan followed by auto-PBSCT has been performed for multiple myeloma, and this treatment has significantly prolonged the period of survival (16) (12, 19, (22) (23) (24) (25) (26) 
